Glomerulonephritis in man is a major cause of morbidity, mortality and end stage renal disease (ESRD) leading to dialysis or transplantation. Autoimmune disease causes most forms of glomerulonephritis. Multiple pathogenic factors are involved in the final expression of glomerulonephritis including the deposition of antibodies and cell mediated immunity. Numerous models have been extensively studied to clarify pathogenic mechanisms, but most likely are induced by methods not directly relevant to man. This investigator has developed a model to examine the pathogenesis of Goodpasture's syndrome, a disease associated with antibody to the glomerular basement membrane, progressive crescentic glomerulonephritis and pulmonary hemorrhage. His studies suggest that a variety of antibodies develop after immunization with the responsible antigen, and that only a subset of these antibodies actually cause disease. Post-translational modification may be critical for expression of the pathogenic antigen. The PI hypothesizes that post-transcriptional modification of the amino acids constituting the immunizing antigen influences its ability to cause nephritis.
The specific aims are to utilize biochemical and molecular methods to 1) identify the antigens which induce the glomerulonephritis, 2) determine if post-translational modification of the amino acids are present and what these modifications might be, and 3) examine the effect of alternation of these modifications on disease induction and course. Strong evidence indicates that the antigen which causes glomerulonephritis in this model is the same antigen or is located on the same protein that causes Goodpasture's syndrome in man. This model provides an opportunity for further study of pathogenic events in autoimmune glomerulonephritis and permits investigations of pathogenesis that cannot be accomplished in vitro. Information derived from this model will provide a better understanding of Goodpasture's syndrome and other types of autoimmune glomerulonephritis. Further, the knowledge resultant from these investigations may provide a basis for the eventual development of specific therapeutic interventions for Goodpasture's syndrome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK055801-03
Application #
6381541
Study Section
Pathology A Study Section (PTHA)
Program Officer
Hirschman, Gladys H
Project Start
1999-05-15
Project End
2003-04-30
Budget Start
2001-05-01
Budget End
2003-04-30
Support Year
3
Fiscal Year
2001
Total Cost
$211,285
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Sung, Sun-Sang; Bolton, Warren K (2010) T cells and dendritic cells in glomerular disease: the new glomerulotubular feedback loop. Kidney Int 77:393-9
Turgut, Faruk; Bolton, Warren Kline (2010) Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 55:928-40
Bolton, W Kline; Chen, Lanlin; Hellmark, Thomas et al. (2005) Molecular mapping of the Goodpasture's epitope for glomerulonephritis. Trans Am Clin Climatol Assoc 116:229-36; discussion 237-8
Bolton, Warren Kline; Chen, Lanlin; Hellmark, Thomas et al. (2005) Epitope spreading and autoimmune glomerulonephritis in rats induced by a T cell epitope of Goodpasture's antigen. J Am Soc Nephrol 16:2657-66
Chen, Lanlin; Hellmark, Thomas; Wieslander, Jorgen et al. (2003) Immunodominant epitopes of alpha3(IV)NC1 induce autoimmune glomerulonephritis in rats. Kidney Int 64:2108-20
Hellmark, Thomas; Chen, Lanlin; Ohlsson, Sophie et al. (2003) Point mutations of single amino acids abolish ability of alpha3 NC1 domain to elicit experimental autoimmune glomerulonephritis in rats. J Biol Chem 278:46516-22
Luo, An-Ming; Fox, Jay W; Chen, Lanlin et al. (2002) Synthetic peptides of Goodpasture's antigen in antiglomerular basement membrane nephritis in rats. J Lab Clin Med 139:303-10
Bolton, W K (2000) Treatment of glomerular diseases: ANCA-negative RPGN. Semin Nephrol 20:244-55